https://scholars.lib.ntu.edu.tw/handle/123456789/631248
標題: | Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies | 作者: | Kulasekararaj, Austin G Griffin, Morag Langemeijer, Saskia Usuki, Kensuke Kulagin, Alexander Ogawa, Masayo Yu, Ji Mujeebuddin, Arshad Nishimura, Jun-Ichi Lee, Jong Wook Peffault de Latour, Régis CHIEN-CHIN LIN 301/302 Study Group |
關鍵字: | breakthrough hemolysis; complement inhibitor; lactate dehydrogenase; paroxysmal nocturnal hemoglobinuria; ravulizumab | 公開日期: | 九月-2022 | 出版社: | WILEY | 卷: | 109 | 期: | 3 | 起(迄)頁: | 205 | 來源出版物: | European journal of haematology | 摘要: | The complement component 5 (C5) inhibitor ravulizumab demonstrated non-inferiority to eculizumab following 26 weeks of treatment in complement inhibitor-naïve and complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH; studies 301 and 302, respectively). This study aims to describe the results of both studies from 27 weeks to 2 years. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/631248 | ISSN: | 0902-4441 1600-0609 |
DOI: | 10.1111/ejh.13783 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。